Bank of America
NAVB

Bank of America’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Bank of America’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-485
Closed -$20K – 8276
2013
Q4 		$20K Hold
485
– – ﹤0.01% 7034
2013
Q3 		$26K Sell
485
-2,420
-83% -$141K ﹤0.01% 6776
2013
Q2 		$155K Buy
+2,905
New +$145K ﹤0.01% 5857

Other funds holding NAVB

BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
ASN
Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $683M AUM 22.58% 1-Year Est. Return

Bank of America's NAVB Position: Q4 2023 in Review

Bank of America sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q4 2023, closing a stake of 1,604 shares — an estimated $143 sold.

Bank of America first reported a position in NAVB in Q2 2013 and held it in 42 quarters. The position peaked at $196K in Q2 2013. 4 funds tracked by Wall St. Rank hold NAVB as of Q4 2023.

  • Bank of America reported no remaining Navidea Biopharmaceuticals Inc. position as of Q4 2023 after selling out during the quarter.
  • Bank of America sold 1,604 Navidea Biopharmaceuticals Inc. shares in Q4 2023, an estimated $143.
  • Bank of America first reported a position in Navidea Biopharmaceuticals Inc. in Q2 2013 and held it in 42 quarters.
  • Bank of America's Navidea Biopharmaceuticals Inc. position peaked at $196K in Q2 2013.
  • 4 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q4 2023.

Based on Bank of America's 13F filing for Q4 2023, filed 14 Feb 2024.